Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02456532 · ClinicalTrials.gov registry record · Phase 4
Safety and Efficacy of Chronic Hypnotic Use 2
A Phase 4 study, sponsored by Henry Ford Health System.
- Completed
- Registry status
- Phase 4
- Development phase
- 41
- Enrollment target
NCT02456532: Completed Phase 4 study, sponsored by Henry Ford Health System.
NCT02456532 is a Phase 4 study that has completed, run by Henry Ford Health System. The registered enrollment target is 41 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (92% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02456532, a Phase 4 study, has completed, sponsored by Henry Ford Health System.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 41 participants
- Enrollment target
Study Summary
This proposal will assess risks for transition from therapeutic hypnotic use to abuse in people with insomnia. The investigators will study a hypothesized at-risk sub-population, insomniacs with hyperarousal, and compare two hypnotics, a drug with mood effects, eszopiclone, versus one without mood effects, zolpidem.
Primary Outcome
instruction to stop nightly hypnotic use over a two-week discontinuation period with option to choose of 1, 2, 3 capsules, if necessary
Interventions
- DRUG placebo
- DRUG Eszopiclone
- DRUG Zolpidem CR
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2015-08-05 |
| Est. Completion | 2022-02-22 |
| Phase | Phase 4 |
What the finished NCT02456532 record still lists
NCT02456532 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 41 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (92% lower).
The record links to 0 conditions, and to 3 interventions - of which placebo is the first listed.
NCT02456532 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02456532 about?
NCT02456532 is a clinical study titled "Safety and Efficacy of Chronic Hypnotic Use 2". This proposal will assess risks for transition from therapeutic hypnotic use to abuse in people with insomnia. The investigators will study a hypothesized at-risk sub-population, insomniacs with hyperarousal, and compare two hypnotics, a drug with mood effects, eszopiclone, versus one without mood e...
What is the current status of trial NCT02456532?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 41 participants. The study started on 2015-08-05. Estimated completion is 2022-02-22.
What interventions are being tested in trial NCT02456532?
The interventions under investigation include: placebo (DRUG), Eszopiclone (DRUG), Zolpidem CR (DRUG).
Who is sponsoring clinical trial NCT02456532?
This trial is sponsored by Henry Ford Health System, which has 234 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02456532's enrollment target sits among peer trials
41 1390th of 2000 higher than 604 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03449238 · 41 participants · Phase 1
Pembrolizumab And Stereotactic Radiosurgery (Srs) Of Selected Brain Metastases In Breast Cancer Patients
- NCT03900793 · 41 participants · Phase 1
Losartan + Sunitinib in Treatment of Osteosarcoma
- NCT04082520 · 41 participants · Phase 2
Lutathera for the Treatment of Inoperable, Progressive Meningioma After External Beam Radiation Therapy
- NCT04220190 · 41 participants · Phase 2
RAPA-501 Therapy for ALS
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI